C4 Therapeutics, Inc. (CCCC) Cash Flow Statement
C4 Therapeutics, Inc. (CCCC) generated -$84.9M of operating cash flow over the twelve months to 2026-06-30, spent $523000 on capital expenditure and had free cash flow of -$85.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CCCCC4 Therapeutics, Inc.Follow CCCC — free
—
Price chart with a free account
- Market cap
- 376.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -105.9 | -106.8 | -65.2 | -98.7 | -84.9 | |
| Capital expenditure | 5.5 | 1.7 | 0.2 | 0.6 | -0.5 | |
| Free cash flow | -111.4 | -108.5 | -65.3 | -99.3 | -85.4 | |
| Share repurchases | 0.0 | 0.1 | 0.2 | 0.2 | — | |
| Stock-based compensation | 30.0 | 27.2 | 29.7 | 19.1 | — |
USD millions · SEC XBRL
C4 Therapeutics, Inc. — questions
- What is C4 Therapeutics, Inc.'s operating cash flow?
- -$84.9M over the twelve months to 2026-06-30.
- How much does C4 Therapeutics, Inc. spend on capital expenditure?
- $523000 over the twelve months to 2026-06-30.
- What is C4 Therapeutics, Inc.'s free cash flow?
- -$85.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from C4 Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.